Key takeaways
- Applied Therapeutics (APLT) has no FDA approval; its lead drug govorestat is under review for galactosemia after a Complete Response Letter.
- CRISPR Therapeutics (CRSP) is the only one of the four with an FDA-approved drug: Casgevy, the first CRISPR-based medicine cleared in the US.
- Outlook Therapeutics (OTLK) and Unicycive Therapeutics (UNCY) both received CRLs citing manufacturing deficiencies and are trading on resubmission review cycles.
- Keyword-matched news feeds conflate the four 'Therapeutics' names, so alerts should fire on tickers, never company names.
- Single small-cap FDA catalysts move one ticker, not NQ or ES, unless multiple decisions cluster in the same week and shift sector sentiment.
Applied Therapeutics news of an FDA approval is easy to misread because three other small caps, CRISPR Therapeutics, Outlook Therapeutics, and Unicycive Therapeutics, sit in the same search results with their own regulatory timelines. This tracker separates all four by ticker, lead indication, latest FDA milestone, and next expected decision date, so you trade the real catalyst instead of a headline that was never theirs.
What is the latest FDA approval news for Applied Therapeutics?
Applied Therapeutics (APLT) has no FDA approval to date. Its lead drug, govorestat, is under review for galactosemia, a rare metabolic disorder, and the company's stock-relevant news flow centers on that single regulatory file rather than a marketed product.
Which indication is under review
Govorestat targets classic galactosemia, where the unapproved drug candidate's fate drives the entire APLT catalyst calendar. For traders, that concentration matters: one FDA action moves the name, and there is no second pipeline asset to dilute the event risk.
What happened at the most recent FDA decision point
The FDA issued a Complete Response Letter for govorestatt rather than an approval, pushing any potential US authorization to a later review cycle. Confirm the current status and any resubmission dates directly on Applied Therapeutics' investor relations site before trading the ticker. If you want the next regulatory action pushed to you instead of polling press releases, join the Tradar waitlist.
Has CRISPR Therapeutics received any FDA approvals recently?
Casgevy: what is approved and for whom
CRISPR Therapeutics (CRSP) holds one FDA approval: Casgevy, a CRISPR-based gene-editing therapy cleared for sickle cell disease and later expanded to transfusion-dependent beta-thalassemia. That approval was the first of its kind in the US, which is why CRSP headlines still move the stock even years after clearance. For catalyst traders, the approved indication is settled news. The edge now comes from what is pending, not what is already priced in.
What pipeline filings could produce the next FDA catalyst
The tradable question is whether new regulatory filings or indication expansions enter review. Any FDA acceptance of a new application, advisory committee date, or decision deadline is a discrete event that can produce an initial move, and the first minutes matter most. Watch the company's own pipeline updates and FDA calendar rather than creator commentary, which by definition arrives after the first 5 to 10 percent of the move. If your watchlist also spans other sectors, Tradar's coverage extends beyond biotech, including a crypto news feed for cross-asset catalyst tracking.
What is the FDA status of Outlook Therapeutics' pipeline?
Outlook Therapeutics (OTLK) has one asset in the clinic: ONS-5010, an ophthalmologic formulation of bevacizumab under review as LYTENAVA for wet AMD. The FDA has not approved it, and the company's regulatory history is defined by complete response letters rather than clean approvals. Each CRL pushed the review cycle back and repriced the stock, which is exactly the kind of headline conflation this article exists to untangle.
ONS-5010 and the CRL history
The FDA issued a complete response letter on ONS-5010's initial application, citing chemistry, manufacturing, and controls deficiencies rather than efficacy failures. Outlook resubmitted, and the review continued. That distinction matters: a CRL over manufacturing is a different trade than a CRL over trial data, and traders who read only the headline "FDA rejects" miss the difference. For context on what a completed review looks like, the FDA's approval of CRISPR Therapeutics' Casgevy shows the endpoint this pipeline has not yet reached (FDA press announcement).
Next FDA milestone and what it means for the stock
OTLK's next regulatory date is set by its resubmission review cycle, so the tradable event is the PDUDA-period decision, not the CRL aftermath. Confirm the current goal date on the company's latest press release before sizing a position, because review timelines on resubmissions have already slipped once. When the decision lands, you want the alert within seconds, not after FinTwit has priced in the first move. We built our comparison of news alerting tools around that gap.
Where does Unicycive Therapeutics stand with FDA review?
Unicycive Therapeutics (UNCY) trades on a single lead asset: oxylanthanum carbonate (OLC), a phosphate binder in development for hyperphosphatemia in patients on dialysis. That focus makes the ticker unusually sensitive to any regulatory headline, since there is no second pipeline story to dilute the catalyst.
Lead asset and indication
OLC targets a large dialysis-adjacent market, and the trade thesis is binary: an approval re-rates the company, a second CRL does the opposite. If you trade the initial move on FDA news, UNCY behaves like a pure event stock, closer to an NADSAQ biotech binary than to an index catalyst that ripples into NQ or ES.
Regulatory setbacks and the path to a decision
The FDA issued a Complete Response Letter on the original NDA, citing manufacturing and facility-related deficiencies rather than questioning efficacy data. Unicycive resubmitted, and the agency's review of that resubmission set the current decision timeline. Track the resubmission acceptance date and the resulting goal date the way you'd track a PDUFA date, because the re-review window is where the priced-in move happens. A status-and-timeline tracker helps here, and we built Tradar to surface exactly these regulatory events as sub-minute alerts so you trade the catalyst, not the recap.
How do FDA decision dates differ across these four therapeutics companies?
The four names sit at very different points in the regulatory cycle, and that difference is the whole trade. One has an approval already in hand, one has a complete response letter history, and two are still working through review. Treating them as interchangeable "FDA catalyst" names is how traders end up positioned on the wrong ticker when a headline drops.
Side-by-side FDA milestone table
| Company | Ticker | Lead indication | Latest FDA milestone | Next expected decision date |
|---|---|---|---|---|
| Applied Therapeutics | APLT | Galactosemia | Complete response letter; resubmission under review | Check latest company guidance |
| CRISPR Therapeutics | CRSP | Sickle cell disease (Casgevy, with Vertex) | FDA approval (first CRISPR-based medicine) | Pipeline expansion milestones, not a single PDUFA date |
| Outlook Therapeutics | OTLK | Wet AMD (LYT-100, ophthalmic bevacizumab) | CRL issued; resubmission path in progress | Check latest company guidance |
| Unicycive Therapeutics | UNC | Hyperphosphatemia in dialysis (oxylanthanum carbonate) | NDA under review following prior CRL | Check latest company guidance |
Dates shift with resubmissions and CRLs, so treat any PDUFA date older than a few weeks as stale. CRISPR's filings and pipeline updates are best verified directly on its investor relations pipeline announcements.
Which companies have near-term catalysts vs completed approvals
CRSP has already cleared the bar: Casgevy is approved, so its catalysts are label and pipeline events rather than a first approval. APLT, OTLK, and UNC are all in the resubmission-and-review zone, where a CRL is a live downside risk and an acceptance letter can itself move the stock pre-market. That split matters for sizing: completed-approval names trade on incremental news, while the review-stage names trade binary.
If you trade the initial move on these headlines, the bottleneck is speed of classification, not coverage. A tool like Tradar compared against Benzinga is built around surfacing the catalyst itself so you can confirm which ticker the headline actually names before the first leg is priced in.
Why do Applied, CRISPR, Outlook, and Unicycive Therapeutics get confused in news searches?
All four companies share the "Therapeutics" suffix, and their tickers sit close together alphabetically. A feed filtering on "Therapeutics" or "FDA" surfaces headlines from all of them, and a trader scanning fast sees "Therapeutics files for FDA approval" without registering which company filed.
How keyword-matched news feeds mix up tickers
Most keyword alerts match on words, not entities. "CRISPR Therapeutics FDA decision" and "Outlook Therapeutics FDA decision" are nearly identical strings, so an alert built on "therapeutics + FDA" fires for both. A headline like "Therapeutics company receives CRL from FDA" reads the same whether it describes Applied, Outlook, or Unicycive, and X posts often drop the company name entirely, leaving just "FDA rejects…".
The cost of trading the wrong 'Therapeutics' headline
If you short the wrong ticker on a rejection headline, you are positioned in a stock with no catalyst while the real mover gaps without you. The information edge belongs to whoever reaches the primary source first, and that starts with knowing which company the headline is actually about.
How can traders track FDA approval news for small-cap biotech stocks?
Primary sources worth checking directly
The company's own press release is the primary source. When Outlook Therapeutics received a complete response letter for ONS-5010 and later resubmitted, the timeline traders needed was in Outlook Therapeutics' own announcement, not in aggregated headlines that arrived after the move.
Setting alerts that fire on the ticker, not the name
The core discipline is alerting on the ticker, never the company name. "Applied Therapeutics" returns results for Applied DNA, Applied Molecular Transport, and Applied UV; a name-based feed mixes four unrelated pipelines into one stream and hands you a catalyst that belongs to someone else. A ticker-verified alert fires only when APLT, CRSP, OTLK, or UCYV is explicitly attached to the headline, which is the difference between trading the actual FDA event and trading a misattributed one. Pair that with the FDA's advisory committee calendar so you know the scheduled dates in advance, and press-release alerts catch the unscheduled ones, like a complete response letter arriving outside any calendar.
How Tradar fits the workflow
Tradar's real-time alerts carry impact and trust scores so you can judge in seconds whether a headline is a primary-source catalyst or recycled commentary. It covers broad market news rather than a curated biotech calendar, so it works best as the alert layer on top of the FDA calendar you check yourself.
Do biotech FDA catalysts move the broader futures market?
Single-stock catalysts vs index-level moves
An FDA decision on Applied, CRISPR, Outlook, or Unicycive moves one ticker, not NQ or ES. A single small-cap approval, even a 50% single-day move, is too small in weight to register in an index that trades on macro data and mega-cap earnings. The edge here is in the stock itself, not the futures contract.
Where biotech news does reach your futures desk is through sentiment. A wave of risk-off headlines, or a sector-wide biotech selloff, can color how NQ and ES open and how traders lean into the session.
When to watch biotech news from a futures desk
Watch biotech catalysts when they cluster: multiple decisions or trial readouts landing the same week can shift risk appetite enough to show up in index flows. Otherwise, treat them as single-stock events and trade the catalyst where it actually lives.
FAQ
Is Applied Therapeutics the same company as CRISPR Therapeutics?
No. Applied Therapeutics (APLT) is developing govorestat for galactosemia and has no FDA approval to date. CRISPR Therapeutics (CRSP) is a separate company that holds the first US approval for a CRISPR-based therapy, Casgevy, cleared for sickle cell disease. They share only the 'Therapeutics' suffix, which is why keyword-matched news feeds surface both under the same search results.
What is a PDUFA date and why does it matter for small-cap biotech trades?
A PDUFA date is the FDA's goal date for completing its review of a drug application. For single-asset small caps like APLT, OTLK, and UNCY, that date is effectively the catalyst calendar: the decision reprices the stock, and resubmissions or CRLs shift it. Treat any PDUFA date older than a few weeks as stale and verify against the latest company guidance.
Which of the four Therapeutics companies already has an FDA-approved drug on the market?
Only CRISPR Therapeutics. Its Casgevy gene-editing therapy is FDA-approved for sickle cell disease and was later expanded to transfusion-dependent beta-thalassemia. Applied, Outlook, and Unicycive all sit in the resubmission-and-review zone, where a complete response letter remains a live downside risk and each name trades binary on regulatory headlines.
What is the best app for crypto trading news, and is it different from biotech catalyst alerts?
The alerting mechanics are the same: verify the asset or ticker attached to the headline and fire the alert within seconds. Tradar covers crypto alongside biotech through one real-time feed with impact and trust scores, so a single tool handles both. The difference is the underlying event calendar: FDA decision dates versus exchange and macro events.
How fast do small-cap biotech stocks move on FDA approval headlines?
The initial move happens in the first minutes, often before commentary catches up, and the first 5 to 10 percent of the move is where the edge sits. Binary single-asset names like UNCY can gap hard on the headline itself. If your alert arrives after FinTwit is already discussing the headline, the repricing is done and you are trading the recap.